Why is btai dropping today

The stock price of BTAI has experienced a significant drop of 13.4%. BioXcel Therapeutics (BTAI) is dropping today due to the following reasons:

1. **Financial Results**: The company reported a quarterly loss of $2.45 per share, which is worse than expected. This resulted in an earnings surprise of -6.52%. Additionally, the company's revenue was only $120,000, missing the estimate and indicating a significant revenue lag. Furthermore, research and development costs increased to $10.3 million, up from $8.0 million year-over-year, primarily due to increased clinical trial activity.
2. **Market Volatility**: The stock has shown significant volatility recently, with a remarkable 138% surge over the past six months. This volatility could be due to market reactions to the company's financial challenges and the uncertainty surrounding its future earnings.
3. **Regulatory Hurdles**: The company's stock was boosted by optimism around an FDA meeting scheduled for August to discuss a potential label expansion for IGALMI. However, the final approval is contingent on the FDA’s review of the complete sNDA filing and the outcome of the SERENITY trial, which adds uncertainty.

In conclusion, BioXcel Therapeutics (BTAI) is dropping today due to a combination of poor financial results, market volatility, and regulatory hurdles.

|code|Ticker|Name|Date|Percentage Change|market_code|
|---|---|---|---|---|---|
|BTAI|BTAI.O|Bioxcel Therapeutics|20250819|-13.58024691358024|186|

|code|Ticker|Name|Date|Pre-Market Percentage Change|market_code|
|---|---|---|---|---|---|
|BTAI|BTAI.O|Bioxcel Therapeutics|20250819|-12.8747795414462|186|